Startups channel feed – Endpoints News

Startups channel feed

Two former Stanford researchers nab a $41M launch round to learn the secrets of the ‘secretome’

3 years ago

Mining from plants and fungi, CNS startup takes leap into psychoactive drugs — complete with $30M to kick things off

3 years ago

'Rulebook of microbial ecology': Pianists launch Concerto to treat eczema, protect crops and get rid of BO

3 years ago

Exclusive: Mt. Everest almost got in the way of a tRNA biotech, but hC Bioscience climbs to Series A extension

3 years ago

Scoop: Calling off an IPO, a cancer and Covid-19 vaccine maker raises a Series C

3 years ago

A Chicago biotech skips the IPO in favor of late-stage Series D for a PhIII Tourette drug

3 years ago

Drug R&D hurdles hamper another biotech as a Jeff Aronin upstart shuts down

3 years ago

An NK cell therapy biotech pulls IPO ambitions weeks after second trial clearance

3 years ago

Leading a $60M launch round, RA Capital backs another 'toad venom' startup

3 years ago

Updated: Samsara backs ex-Gilead duo's amalgamation of NASH, liver drug assets from former employer, other biopharmas

3 years ago

That secretive ARCH biotech with two antibodies from MorphoSys? It’s now got $120M

3 years ago

Under hub-and-spoke biotech, serial founders launch new startup hoping to make gene therapies for the eye

3 years ago

Intrinsic wanted an IPO. Instead, it's a SPAC for the gut-brain microbiome biotech

3 years ago

Glyn Edwards takes chairman role at UK oncolytic virus startup emerging out of stealth

3 years ago

PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors

3 years ago

A Texas-Illinois cancer biotech searches for more Series B capital two years after extension

3 years ago

Playboy, digital health, electric vehicles and now cancer drugs: A mountainous SPAC journey

3 years ago

Scoop: Carisma stole CAR-M Thunder for a while, but a Utah biotech is quietly raising funds to enter the fray

3 years ago

Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A

3 years ago

Scoop: After hep B setback, an OrbiMed-backed NASH biotech hunts for partners as it raises Series C

3 years ago

Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery

3 years ago

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

3 years ago

Josh Bilenker, Jeff Engelman quiet on everything behind their $735M 'outer edge' startup

3 years ago

Six biotechs merge to take on BridgeBio, Abeona in 'butterfly skin' disease, with eyes also set on Duchenne

3 years ago

First page Previous page 36 37 383940 41 42 Next page Last page